The Medical Developments International Ltd (ASX: MVP) share price has returned from its trading halt with a bang.
In morning trade, the medical device company’s shares are up a massive 32% to $4.50.
Why is the Medical Developments International share price shooting higher?
The Medical Developments International share price returned to trade this morning following the release of an announcement relating to its US aspirations for the Penthrox (aka the green whistle) product.
According to the release, the US Food and Drug Administration (FDA) has unconditionally lifted the agency’s clinical hold on Penthrox.
As a result, this means that Medical Developments International can immediately begin preparing for its Phase III US clinical trial.
The release explains that the trial will be conducted on a targeted trauma and associated pain patient group and is expected to run for two years. The company intends to commence recruitment for the trial in late 2022. This means a long-awaited US launch is now a possibility in the coming years.
Management commentary
Medical Developments International’s CEO, Brent MacGregor, was delighted with the news.
He said: “We are thrilled with this news which allows us to move forward quickly with preparations for our clinical trial. After years of hard work, our team is buoyed by the prospect of bringing the many benefits of Penthrox to the US market. This will strongly complement our growing Penthrox success in Europe, and fully supports our further investment in the product.”
This sentiment was echoed by the company’s Chair, Gordon Naylor.
He commented: “This news is important as it brings Penthrox a step closer to licensure in the US market and because the FDA is seen as a global regulatory leader. Our renewed focus on the core business continues to yield results.”
The post Why the Medical Developments International (ASX:MVP) share price is rocketing 32% higher appeared first on The Motley Fool Australia.
Should you invest $1,000 in MVP right now?
Before you consider MVP, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and MVP wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/qU5PxET
Leave a Reply